Natera, Inc. (NASDAQ:NTRA) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 8,233.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 397,924 shares of the medical research company's stock after acquiring an additional 393,149 shares during the quarter. SG Americas Securities LLC owned 0.29% of Natera worth $56,270,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its holdings in Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after buying an additional 2,036,396 shares in the last quarter. Norges Bank purchased a new position in shares of Natera in the fourth quarter worth about $224,040,000. Raymond James Financial Inc. purchased a new position in Natera during the fourth quarter worth about $146,419,000. Finally, Vanguard Group Inc. raised its stake in Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after purchasing an additional 879,463 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 495 shares of the company's stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $150.74, for a total value of $74,616.30. Following the completion of the sale, the chief financial officer now owns 76,312 shares in the company, valued at $11,503,270.88. This represents a 0.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Fesko sold 343 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $145.55, for a total transaction of $49,923.65. Following the completion of the sale, the insider now owns 156,946 shares of the company's stock, valued at approximately $22,843,490.30. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,275 shares of company stock worth $9,485,023. 7.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. UBS Group lifted their price target on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. BTIG Research reiterated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Finally, Piper Sandler lifted their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Up 0.9%

Shares of NASDAQ:NTRA traded up $1.54 during trading on Wednesday, hitting $166.76. 1,208,807 shares of the company were exchanged, compared to its average volume of 1,407,924. The stock has a market capitalization of $22.77 billion, a P/E ratio of -94.75 and a beta of 1.74. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The firm's 50 day moving average price is $153.38 and its 200-day moving average price is $158.62.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's revenue was up 36.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) EPS. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.